Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Vanins are enzymes that convert pantetheine to pantothenic acid (vitamin B5). Insights into the function of vanins have evolved lately, indicating
vanin-1
to play a role in inflammation, oxidative stress and cell migration. Moreover,
vanin-1
has recently gained attention as a novel modulator of hepatic glucose and lipid metabolism. In the present study, we investigated the role of
vanin-1
in the development of hepatic steatosis and insulin resistance in animal models of
obesity
and diabetes. In addition, we evaluated the potency of RR6, a novel pharmacological
vanin-1
inhibitor, as an anti-diabetic drug. Increased
vanin
activity was observed in plasma and liver of high fat diet (HFD)-induced obese mice, as well as ZDF-diabetic rats. Ablation of
vanin-1
(Vnn1(-/-) mice) mildly improved glucose tolerance and insulin sensitivity in HFD-fed mice, but had no effects on body weight, hepatic steatosis or circulating lipid levels. Oral administration of RR6 for 8 days completely inhibited plasma
vanin
activity, but did not affect hepatic glucose production, insulin sensitivity or hepatic steatosis in ZDF-diabetes rats. In conclusion, absence of
vanin-1
activity improves insulin sensitivity in HFD-fed animals, yet short-term inhibition of
vanin
activity may have limited value as an anti-diabetic strategy.
...
PMID:Genetic and pharmacological inhibition of vanin-1 activity in animal models of type 2 diabetes. 2693 16
